Delivery Order SPE2DB24D3013-SPE2DB25FFQHJ
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $16,095.26 to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Gemtesa 75 mg tablets (90-count units). This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of September 10, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) under a firm fixed price contract valued at $3,328.73. The award, issued on August 18, 2025, with an ultimate completion date of August 19, 2025, represents a competitive, non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance and is a major pharmaceutical distributor providing critical medical supplies to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $52,500.45. This is a firm fixed price delivery order with an ultimate completion date of July 28, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed-price contract valued at $61,502.26. This non-set-aside competitive award is categorized as a delivery order, with an ultimate completion date of July 29, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $75,373.59 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units). This firm fixed-price contract, awarded on August 11, 2025, represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The contract contains no set-aside...
- The Defense Logistics Agency awarded a $7,772.26 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Gemtesa 75 mg tablets (30-count units). The contract represents a firm fixed price, non-set-aside award with an ultimate completion date of September 4, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,478.60 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) on August 21, 2025, with a completion date of August 22, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $7,437.20 to AmerisourceBergen Drug Corp for Gemtesa 75 mg tablets (90-count) on August 28, 2025, with completion targeted for August 29, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to the pharmaceutical distributor's Corporate Office, with performance occurring at the company's headquarters in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded a $8,938.51 delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Gemtesa 75 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation, with an ultimate completion date of September 12, 2025. The award will be performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Gemtesa 75 mg tablets (30-count units) with a ceiling value of $7,558.96. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and running through December 2026. The contract was competitively awarded with no set-aside designation and...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFQHJDelivery Order
The Defense Logistics Agency awarded a competitive delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Gemtesa 75 mg tablets (30-unit package) with a ceiling value of $7,910.41. The contract employs firm fixed pricing and is scheduled for completion by September 10, 2025. This delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical support vehicle that extends through December 2026. The award represents no set-aside designation, indicating the contract was competitively procured on an unrestricted basis. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs across military and veteran healthcare systems. The company maintains a significant portfolio of federal contracts through the DLA Medical Supply Chain, delivering a comprehensive range of pharmaceutical products including specialty medications, brand-name and generic drugs, and medical supplies across multiple therapeutic domains. This delivery order for Gemtesa (mirabegron), used in treating overactive bladder, exemplifies the company's role as a critical vendor supporting Defense Health Agency requirements and broader federal healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.9k | 9/9/25 |